Century Therapeutics, Inc. Operating Cash Flow
Century Therapeutics, Inc. (IPSC) reported Operating Cash Flow of -$45.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- Century Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$19.83M.
- Century Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$25.26M.
- Century Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$16.08M.
- Century Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$25.58M.
- Century Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$103.88M.
- Century Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$110.14M.
- Century Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$88.35M, a 728.72% decline from fiscal 2022.
- Century Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was $14.05M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$19.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$45.10M 10-Q · filed 2026-08-12 | -$61.17M derived: sum of 3 quarters · filed 2026-08-12 | -$86.76M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | -$25.26M 10-Q · filed 2026-05-13 | -$41.34M derived: sum of 2 quarters · filed 2026-05-13 | -$66.92M derived: sum of 3 quarters · filed 2026-05-13 | -$94.52M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | -$16.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$41.66M derived: sum of 2 quarters · filed 2026-03-12 | -$69.25M derived: sum of 3 quarters · filed 2026-08-12 | -$103.88M 10-K · filed 2026-03-12 | |
| 2025-09-30 | -$25.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$53.18M derived: sum of 2 quarters · filed 2026-08-12 | -$87.80M 10-Q · filed 2025-11-13 | -$112.02M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$27.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$62.22M 10-Q · filed 2026-08-12 | -$86.44M derived: sum of 3 quarters · filed 2026-08-12 | -$114.77M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-03-31 | -$34.62M 10-Q · filed 2026-05-13 | -$58.85M derived: sum of 2 quarters · filed 2026-05-13 | -$87.18M derived: sum of 3 quarters · filed 2026-05-13 | -$114.51M derived: sum of 4 quarters · filed 2026-05-13 | |
| 2024-12-31 | -$24.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$52.55M derived: sum of 2 quarters · filed 2026-03-12 | -$79.89M derived: sum of 3 quarters · filed 2026-03-12 | -$110.14M 10-K · filed 2026-03-12 | |
| 2024-09-30 | -$28.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$55.66M derived: sum of 2 quarters · filed 2025-11-13 | -$85.91M 10-Q · filed 2025-11-13 | -$112.14M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$27.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$57.58M 10-Q · filed 2025-08-14 | -$83.81M derived: sum of 3 quarters · filed 2025-08-14 | -$97.46M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | -$30.25M 10-Q · filed 2025-05-15 | -$56.48M derived: sum of 2 quarters · filed 2025-05-15 | -$70.13M derived: sum of 3 quarters · filed 2025-05-15 | -$89.38M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$26.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$39.88M derived: sum of 2 quarters · filed 2025-03-19 | -$59.13M derived: sum of 3 quarters · filed 2025-03-19 | -$88.35M 10-K · filed 2025-03-19 | |
| 2023-09-30 | -$13.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$32.90M derived: sum of 2 quarters · filed 2024-11-05 | -$62.12M 10-Q · filed 2024-11-05 | -$85.03M derived: sum of 4 quarters · filed 2024-11-05 | |
| 2023-06-30 | -$19.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$48.47M 10-Q · filed 2024-08-08 | -$71.38M derived: sum of 3 quarters · filed 2024-08-08 | -$95.61M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$29.22M 10-Q · filed 2024-05-09 | -$52.13M derived: sum of 2 quarters · filed 2024-05-09 | -$76.36M derived: sum of 3 quarters · filed 2024-05-09 | -$101.92M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | -$22.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$47.15M derived: sum of 2 quarters · filed 2024-03-14 | -$72.70M derived: sum of 3 quarters · filed 2024-03-14 | $14.05M 10-K · filed 2024-03-14 | |
| 2022-09-30 | -$24.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$49.79M derived: sum of 2 quarters · filed 2023-11-09 | $36.96M 10-Q · filed 2023-11-09 | $12.61M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$25.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $61.20M 10-Q · filed 2023-08-09 | $61.20M 10-Q · filed 2022-08-11 | $36.85M derived: sum of 3 quarters · filed 2023-08-09 | $12.86M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $86.75M 10-Q · filed 2023-05-11 | $62.40M derived: sum of 2 quarters · filed 2023-05-11 | $38.42M derived: sum of 3 quarters · filed 2023-05-11 | $19.93M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$24.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$48.33M derived: sum of 2 quarters · filed 2023-03-16 | -$66.82M derived: sum of 3 quarters · filed 2023-03-16 | -$89.00M 10-K · filed 2023-03-16 | |
| 2021-09-30 | -$23.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$42.47M derived: sum of 2 quarters · filed 2022-11-10 | -$64.65M 10-Q · filed 2022-11-10 | -$77.87M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | -$18.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$40.67M 10-Q · filed 2022-08-11 | -$53.89M derived: sum of 3 quarters · filed 2022-08-11 | -$63.11M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$22.18M 10-Q · filed 2022-05-16 | -$35.40M derived: sum of 2 quarters · filed 2022-05-16 | -$44.62M derived: sum of 3 quarters · filed 2022-05-16 | ||
| 2020-12-31 | -$13.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$22.45M derived: sum of 2 quarters · filed 2022-03-17 | -$41.27M 10-K · filed 2022-03-17 | ||
| 2020-09-30 | -$9.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$28.05M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | -$18.82M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |